Hexter Joshua sold $611K of ORMP
Hexter Joshua (COO & CBO) sold 137,000 shares of ORAMED PHARMACEUTICALS INC. (ORMP) at $4.46 ($0.61M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the reported open-market sale of 137,000 shares by the COO & CBO on 2026-07-01, totaling $611,431, under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor insider activity for sentiment, but 10b5-1 sales are usually lower-signal than discretionary sales.
What to watch
The filing does not disclose reasons for the sale beyond the plan; without additional context (e.g., concurrent buys, option exercises, or changes in guidance), trading impact should be limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Oramed Pharmaceuticals, Inc. (ORMP).
Ticker impact
ORMP COO & CBO Hexter Joshua sold 137,000 shares on 2026-07-01 under a pre-arranged 10b5-1 plan, worth $611,431.
Low near-term impact; any reaction is likely muted and sentiment-driven.
The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal; this is company-specific insider activity with no sector-wide catalyst described.
None indicated; no broader market or peer read-across in the filing details.
None indicated; no international transaction or regulatory action mentioned.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.
Key entities
- public_companyORMP
Oramed Pharmaceuticals, Inc.; subject of the insider Form 4 transaction disclosure.
- insiderHexter Joshua
COO & CBO who sold 137,000 shares under a pre-arranged 10b5-1 plan.